论文部分内容阅读
目的探讨表皮生长因子受体(E G F R)与核苷酸切除修复交叉组l(E R C C 1)的表达在非小细胞肺癌(NSCLC)中的临床意义。方法用免疫组化SP法检测84例(NSCLC)患者EGFR和ERCC1的表达情况。结果 EGFR和ERCC1阳性表达与患者的性别、年龄、肿瘤组织学类型、分期无关(P>0.05)。EGFR或ERCC1阴性的晚期NSCLC患者的化疗有效率高于阳性患者(P均<0.05)。EGFR或ERCC1阴性的晚期NSCLC患者的疾病进展时间(TTP)、中位生存时间(MST)均长于阳性表达组(P均<0.05)。结论认为EGFR和ERCC1的联合检测可以预测NSCLC患者铂类药物辅助化疗的疗效。
Objective To investigate the clinical significance of the expression of epidermal growth factor receptor (E G F R) and nucleotide excision repair group (E R C C 1) in non-small cell lung cancer (NSCLC). Methods Immunohistochemical SP method was used to detect the expression of EGFR and ERCC1 in 84 cases (NSCLC). Results The positive expression of EGFR and ERCC1 was not related to the gender, age, tumor histological type and stage (P> 0.05). Chemotherapy was more effective in patients with EGFR or ERCC1-negative advanced NSCLC than in those with positive (P <0.05). Patients with EGFR or ERCC1-negative advanced NSCLC had longer duration of disease (TTP) and longer median survival time (MST) than those with positive expression (all P <0.05). The conclusion is that the combined detection of EGFR and ERCC1 can predict the efficacy of adjuvant platinum-based chemotherapy in patients with NSCLC.